Multiple Sclerosis Patients Talk Medical Marijuana

Originally shared by MarijuanaDoctors.com

Multiple Sclerosis Patients Talk Medical Marijuana
Source: http://ow.ly/RM3WV

More and more evidence is accumulating that denying medical cannabis to patients suffering from diseases likes multiple sclerosis should no longer be acceptable under any state’s law.

Laboratory, pre-clinical and clinical trials have all backed up the use of medical cannabis products for the disease, and patients back up what the science is saying.

Patients have a right to safe, life-saving botanicals and they’re not waiting around for the federal government or recalcitrant states. They’re getting recommendations for cannabis in one of 23 medical marijuana states, and seeking out formulations like mouth sprays and CBD-rich edibles that specifically help with M.S. symptoms.

Over 400,000 people in the United States and about 2.5 million people around the world have Multiple Sclerosis (MS). About 200 new cases are diagnosed each week in the United States alone. While most people are diagnosed between the ages of 20-40, MS also affects children and older people.

MS is the most common and chronic neurological disease of young adults. The worst part is that the degenerative disease is complex and most people won’t experience all the symptoms, at least not at the same time.

Cannabinoids like THC and CBD have proven to be highly effective in helping patients manage many of the symptoms of multiple sclerosis (MS). Oromucosal (mouth) sprays like Sativex (R) have been approved as adjunctive treatment for neuropathic pain in Canada. Combined cannabinoid medicines like these are also being tested to help MS patients cope with spasticity, one of the most disabling symptoms of the disease.

“Thousands of randomized, controlled trials indicate that that in addition to symptom management, cannabinoid therapy also slows the neurodegenerative processes that ultimately lead to chronic disability in patients with MS,” a 2005 study found.
http://ow.ly/RM3WV